Sign In
Buy RGNX
$9.95
+0.88 (+9.70%)
At Close: Jun 23, 2026
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
11:51am, Tuesday, 23'rd Jun 2026
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy
09:23am, Monday, 22'nd Jun 2026
Regenxbio Inc. (NASDAQ:RGNX) on Monday said it aligned with the Food and Drug Administration (FDA) regarding the next steps needed for a potential accelerated approval of Navsunli (RGX-121, clemidsoge
FDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE ® study will be reviewed on an expedited basis for approval via the accelerated approval pathway The Company
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
07:01am, Monday, 22'nd Jun 2026
The U.S. Food and Drug Administration will reverse its earlier rejection of a rare-disease therapy from Regenxbio , the Wall Street Journal reported on Monday
FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
06:30am, Monday, 22'nd Jun 2026
The company plans to refile its application for its gene therapy for a fatal brain disease after the FDA dropped demands to give a placebo to some study subjects.
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
04:20pm, Friday, 22'nd May 2026
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
REGENXBIO to Participate in Upcoming Investor Conferences
04:05pm, Monday, 18'th May 2026
ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2026 RBC Capital Markets Global Healthcare Confer
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
08:30pm, Thursday, 14'th May 2026
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
12:03pm, Thursday, 14'th May 2026
REGENXBIO Inc. (NASDAQ:RGNX) on Thursday released topline and interim functional data from the pivotal Phase 1/2/3 AFFINITY DUCHENNE trial evaluating RGX-202, its investigational gene therapy for Duch
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
09:30am, Thursday, 14'th May 2026
Regenxbio (RGNX) came out with a quarterly loss of $1.72 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to earnings of $0.12 per share a year ago.
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
07:10am, Thursday, 14'th May 2026
Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE ® study of RGX-202 Primary endpoint achieved with high statistical significance Statistically significant correlati
Regenxbio's muscle disorder therapy meets main goal in late-stage study
07:04am, Thursday, 14'th May 2026
Regenxbio said on Thursday that its experimental therapy to treat a muscle-wasting disorder met the main goal in a late-stage study.
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
07:00am, Thursday, 14'th May 2026
Achieved primary endpoint with high statistical significance; 93% of patients achieved microdystrophin expression above 10% (p
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
07:05am, Thursday, 07'th May 2026
ROCKVILLE, Md., May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
07:05am, Wednesday, 06'th May 2026
-- Company will also report first quarter 2026 financial results and operational highlights -- ROCKVILLE, Md., May 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will h
